Home/Investors/OrbiMed

OrbiMed

Biotech Investor · 4 portfolio companies

Portfolio

4

Combined Value

$3.1B

Focus Areas

13

Top Stage

Commercial

Investment Focus

Cardiorenal Metabolic Gastroenterology Nephrology Oncology Immunology Infectious Diseases Neuroscience Cardiovascular Fibrotic Diseases Metabolic Diseases Neurodegenerative Diseases Neurology

Portfolio Companies

Company	Stage	Valuation	Focus
Ardelyx	Commercial	$1.3B	Cardiorenal, Metabolic
AbCellera	Pre-clinical	$1.0B	Oncology, Immunology
Tectonic Therapeutic	Phase 1	$561.0M	Cardiovascular, Fibrotic Diseases
Alector	Phase 3	$226.2M	Neurodegenerative Diseases, Neurology

Frequent Co-Investors

Polaris Partners2 shared Public market investors1 shared Frazier Healthcare Partners1 shared RA Capital Management1 shared Peter Thiel1 shared New Enterprise Associates1 shared DCVC1 shared Eli Lilly1 shared